再生元制药公司在AAAAI年会上展示了其免疫学管道的最新进展Regeneron Pharmaceuticals Presents Updates on Immunology Pipeline at AAAAI Annual Meeting

动脉网02-10

by GOAI由GOAI生成Share To分享到Regeneron Pharmaceuticals presented updates on its expanding immunology portfolio and pipeline at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610621562?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-10 21:09","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610621562","market":"us","top_or_hot":-1,"title":"再生元制药公司在AAAAI年会上展示了其免疫学管道的最新进展Regeneron Pharmaceuticals Presents Updates on Immunology Pipeline at AAAAI Annual Meeting","media":"动脉网","content":"<div>\n<p>by GOAI由GOAI生成Share To分享到Regeneron Pharmaceuticals presented updates on its expanding immunology portfolio and pipeline at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210211130a493c179&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再生元制药公司在AAAAI年会上展示了其免疫学管道的最新进展Regeneron Pharmaceuticals Presents Updates on Immunology Pipeline at AAAAI Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再生元制药公司在AAAAI年会上展示了其免疫学管道的最新进展Regeneron Pharmaceuticals Presents Updates on Immunology Pipeline at AAAAI Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 21:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210211130a493c179&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by GOAI由GOAI生成Share To分享到Regeneron Pharmaceuticals presented updates on its expanding immunology portfolio and pipeline at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210211130a493c179&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210211130a493c179&s=b","article_id":"2610621562","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210211130a493c179&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610621562","pubTimestamp":1770728940,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"During the presentation, Regeneron highlighted progress across multiple investigational therapies targeting allergic and inflammatory conditions. These included updates on clinical trials evaluating potential treatments for chronic spontaneous urticaria, food allergies, and other immune-related disorders.在演讲中，Regeneron 强调了其在针对过敏和炎症性疾病的多项研究性疗法中取得的进展。The company also discussed ongoing research into monoclonal antibodies designed to modulate specific pathways involved in allergic responses. Additionally, Regeneron shared data from studies exploring innovative therapeutic strategies to address unmet needs in allergy treatment..该公司还讨论了正在进行的单克隆抗体研究，这些抗体旨在调节与过敏反应相关的特定通路。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4588":"碎股","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","REGN":"再生元制药公司"},"translate_title":"Regeneron Pharmaceuticals Presents Latest Advances in Its Immunology Pipeline at AAAAI Annual Meeting Regeneron Pharmaceuticals Presents Updates on Immunology Pipeline at AAAAI Annual Meeting","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5},"content_text":"by GOAI由GOAI生成Share To分享到Regeneron Pharmaceuticals presented updates on its expanding immunology portfolio and pipeline at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. The company showcased several novel approaches aimed at addressing allergies and related conditions, emphasizing advancements in treatments for various immune-mediated diseases..再生元制药公司在美国过敏、哮喘和免疫学学会（AAAAI）年会上展示了其不断扩展的免疫学产品组合和研发管线的最新进展。公司重点介绍了几种针对过敏及相关疾病的新方法，强调了在多种免疫介导疾病的治疗方面取得的进展。During the presentation, Regeneron highlighted progress across multiple investigational therapies targeting allergic and inflammatory conditions. These included updates on clinical trials evaluating potential treatments for chronic spontaneous urticaria, food allergies, and other immune-related disorders.在演讲中，Regeneron 强调了其在针对过敏和炎症性疾病的多项研究性疗法中取得的进展。这些进展包括评估慢性自发性荨麻疹、食物过敏及其他免疫相关疾病潜在治疗方案的临床试验更新。The company also discussed ongoing research into monoclonal antibodies designed to modulate specific pathways involved in allergic responses. Additionally, Regeneron shared data from studies exploring innovative therapeutic strategies to address unmet needs in allergy treatment..该公司还讨论了正在进行的单克隆抗体研究，这些抗体旨在调节与过敏反应相关的特定通路。此外，再生元分享了探索创新治疗策略以解决过敏治疗中未满足需求的研究数据。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1For any suggestion and feedback, please contact us.如果有任何建议和反馈，请联系我们。Date: February 10, 2026日期：2026年2月10日©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 保留所有权利。与我们合作：[email protected]电子邮件地址Author作者GOAIGOAIRelated Post相关文章","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610621562","isCrawlerRequest":true}